TY - JOUR
T1 - Well-Controlled Comparative Study and Open Clinical Study of 0.05% Hydrocortisone-17-Butyrate Ointment (TS-1020)/TS-1020 Clinical Study Group
AU - Ueda, Hiroshi
AU - Hayakawa, Ritsuko
AU - Matsunaga, Kayoko
PY - 1989/10/17
Y1 - 1989/10/17
N2 - TS-1020 (TS) is a proprietary steroidal ointment which contains 0.05% hydrocortisone-17-butyrate. Locoid® Ointment (LO), which contains 0.1% of the topical steroid, has been generally used since 1975 as an ethical steroidal ointment. The vehicles of the two ointments are the same. In order to elucidate the clinical efficacy and safety of TS, well-controlled comparative study was perfromed in comparison with LO in 85 patients with moist type of eczema for 1 week application. The results showed that the efficacy rate of TS was 78.1%, whereas that of LO was 79.5%. The difference between TS and LO was not statistically significant. Then open clinical study of TS was done in 218 cases with moist type of eczema, lichenificated type of eczema, prurigo and hand eczema. The efficacy rates were 83. 3% (67/126 cases) in moist type of eczema, 79.6% (31/54 cases) in lichenificated type of eczema and 69.0% (16/29 cases) in chronic prurigo and hand eczema. Any side effect was noticed in the open clinical study. Therefore we concluded that TS is an excellent proprietary steroidal ointment with efficacy and safety.
AB - TS-1020 (TS) is a proprietary steroidal ointment which contains 0.05% hydrocortisone-17-butyrate. Locoid® Ointment (LO), which contains 0.1% of the topical steroid, has been generally used since 1975 as an ethical steroidal ointment. The vehicles of the two ointments are the same. In order to elucidate the clinical efficacy and safety of TS, well-controlled comparative study was perfromed in comparison with LO in 85 patients with moist type of eczema for 1 week application. The results showed that the efficacy rate of TS was 78.1%, whereas that of LO was 79.5%. The difference between TS and LO was not statistically significant. Then open clinical study of TS was done in 218 cases with moist type of eczema, lichenificated type of eczema, prurigo and hand eczema. The efficacy rates were 83. 3% (67/126 cases) in moist type of eczema, 79.6% (31/54 cases) in lichenificated type of eczema and 69.0% (16/29 cases) in chronic prurigo and hand eczema. Any side effect was noticed in the open clinical study. Therefore we concluded that TS is an excellent proprietary steroidal ointment with efficacy and safety.
UR - http://www.scopus.com/inward/record.url?scp=0024549719&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024549719&partnerID=8YFLogxK
U2 - 10.11340/skinresearch1959.31.248
DO - 10.11340/skinresearch1959.31.248
M3 - Article
AN - SCOPUS:0024549719
SN - 0018-1390
VL - 31
SP - 248
EP - 267
JO - skin research
JF - skin research
IS - 2
ER -